Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

88.35USD
11:19am EDT
Price Change (% chg)

$0.14 (+0.16%)
Prev Close
$88.21
Open
$88.59
Day's High
$88.59
Day's Low
$88.16
Volume
128,094
Avg. Vol
241,002
52-wk High
$91.65
52-wk Low
$71.00

NVS.N

Chart for NVS.N

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.52
Market Cap (Mil.): $239,565.59
Shares Outstanding (Mil.): 2,706.19
Dividend: 2.76
Yield (%): 3.13

Financials

  NVS.N Industry Sector
P/E (TTM): 22.50 35.68 36.12
EPS (TTM): 3.92 -- --
ROI: 10.09 18.88 18.15
ROE: 14.16 19.60 18.97
Search Stocks

Swiss stocks - Factors to watch on July 30

ZURICH, July 30 - The following are some of the main factors expected to affect Swiss stocks on Wednesday:

12:46am EDT

Novartis says Alcon glaucoma treatment approved in EU

ZURICH - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

28 Jul 2014

Novartis says Alcon glaucoma treatment approved in EU

ZURICH, July 28 - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease.

28 Jul 2014

U.S. paves way for Novartis to copy Amgen biotech drug

- U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.

24 Jul 2014

U.S. paves way for Novartis to copy Amgen biotech drug

July 24 - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.

24 Jul 2014

BUZZ-U.S. Stocks on the Move-Counterpath, Euro Tech, Herbalife

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus. The Dow Jones i

21 Jul 2014

BUZZ-U.S. Stocks on the Move-Counterpath, Euro Tech, Intercloud

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and Gaza continue to garner investor focus. The Dow Jones i

21 Jul 2014

Will you get burned by following the hot money in ETFs?

CHICAGO - All too often, I see investors heading in the wrong direction en masse. They buy stocks at the top of the market or bonds when interest rates are heading up.

21 Jul 2014

COLUMN-Will you get burned by following the hot money in ETFs?

(The opinions expressed here are those of the author, a columnist for Reuters.)

21 Jul 2014

BUZZ-U.S. Stocks on the Move-Euro Tech, Extreme Networks, Hasbro

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Monday, following the sharpest moves in indexes in the past three months during the two previous sessions, as developments in Ukraine and the Gaza Strip continue to garner investor focus. The D

21 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $102.11 +0.15
Pfizer Inc. (PFE.N) $29.18 -0.29
Merck & Co., Inc. (MRK.N) $57.71 -0.87
Roche Holding Ltd. (ROG.VX) CHF266.70 +0.90
Abbott Laboratories (ABT.N) $42.74 -0.01
Sanofi SA (SASY.PA) €76.97 +0.15
AstraZeneca plc (AZN.L) 4,356.00p +33.50
GlaxoSmithKline plc (GSK.L) 1,427.00p +8.00
Eli Lilly and Co (LLY.N) $62.50 -0.27
Bristol-Myers Squibb Co (BMY.N) $50.97 -0.04

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks